| 1 |
Shan W, Wu G, Huang Y, Zeng H, Xia W, Lin Z, Xu B. Adverse events in lymphoma patients treated with phosphoinositide 3 kinase Inhibitor in clinical trials: a meta-analysis. Ann Hematol 2022;101:1741-53. [PMID: 35688904 DOI: 10.1007/s00277-022-04876-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 2 |
Matasar MJ, Hiemeyer F, Childs BH, Zinzani PL. PI3K inhibitors in haematological malignancies. The Lancet Oncology 2022;23:e365. [DOI: 10.1016/s1470-2045(22)00332-1] [Reference Citation Analysis]
|
| 3 |
Shouse G, Danilova OV, Danilov AV. Current status of phosphoinotiside-3 kinase inhibitors in blood cancers. Curr Opin Oncol 2022. [PMID: 35855508 DOI: 10.1097/CCO.0000000000000871] [Reference Citation Analysis]
|
| 4 |
Forero-Torres A, Chandler JC, Iyer SP, Kanate AS, Quinlan M, Hoever P, Izquierdo M, Davis J, Madan S. Phase 1 Study Evaluating Pharmacokinetics and Tolerability of Ofatumumab Combined With Bendamustine in Patients With Indolent B-Cell Non-Hodgkin's Lymphoma. Clin Pharmacol Drug Dev 2022. [PMID: 35819310 DOI: 10.1002/cpdd.1133] [Reference Citation Analysis]
|
| 5 |
Richardson NC, Kasamon Y, Pazdur R, Gormley N. The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint. The Lancet Oncology 2022. [DOI: 10.1016/s1470-2045(22)00200-5] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 6 |
Liu W, Ping L, Xie Y, Sun Y, Du T, Niu Y, Cisternas G, Huang F, Garcia-Vargas J, Childs BH, Mehra A, Reschke S, Wang X, Song Y, Zhu J. A phase I pharmacokinetic study of copanlisib in Chinese patients with relapsed indolent non-Hodgkin lymphoma. Cancer Chemother Pharmacol 2022. [PMID: 35322287 DOI: 10.1007/s00280-022-04417-3] [Reference Citation Analysis]
|
| 7 |
Tang X, Chen X, Zhang T, Jiang J. Copanlisib plus rituximab combination therapy vs. rituximab monotherapy for relapsed indolent non-Hodgkin lymphoma: a cost-effectiveness analysis. Ann Transl Med 2022;10:352. [PMID: 35433977 DOI: 10.21037/atm-22-1159] [Reference Citation Analysis]
|
| 8 |
Raychaudhuri R, Ujjani C. Targeted Therapy for Relapsed/Refractory Follicular Lymphoma: Focus on Clinical Utility of Tazemetostat. OTT 2022;Volume 15:193-9. [DOI: 10.2147/ott.s267011] [Reference Citation Analysis]
|
| 9 |
Serganova I, Chakraborty S, Yamshon S, Isshiki Y, Bucktrout R, Melnick A, Béguelin W, Zappasodi R. Epigenetic, Metabolic, and Immune Crosstalk in Germinal-Center-Derived B-Cell Lymphomas: Unveiling New Vulnerabilities for Rational Combination Therapies. Front Cell Dev Biol 2021;9:805195. [PMID: 35071240 DOI: 10.3389/fcell.2021.805195] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 10 |
Zhang B, Li X, Yin T, Qin D, Chen Y, Ma Q, Shu P, Wang Y, Marchetti C. Neurotoxicity of Tumor Immunotherapy: The Emergence of Clinical Attention. Journal of Oncology 2022;2022:1-12. [DOI: 10.1155/2022/4259205] [Reference Citation Analysis]
|
| 11 |
Qualls D, Salles G. Prospects in the management of patients with follicular lymphoma beyond first-line therapy. Haematologica 2022;107:19-34. [PMID: 34985231 DOI: 10.3324/haematol.2021.278717] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 12 |
Leslie LA. Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas. Curr Treat Options Oncol 2021;22:111. [PMID: 34694508 DOI: 10.1007/s11864-021-00909-1] [Reference Citation Analysis]
|
| 13 |
Tsimberidou AM, Shaw JV, Juric D, Verschraegen C, Weise AM, Sarantopoulos J, Lopes G, Nemunaitis J, Mita M, Park H, Ellers-Lenz B, Tian H, Xiong W, Kaleta R, Kurzrock R. Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer. J Hematol Oncol 2021;14:127. [PMID: 34407844 DOI: 10.1186/s13045-021-01132-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 14 |
Pongas G, Cheson B. Recent Advances in the Management of Patients with Relapsed/Refractory Follicular Lymphoma. Blood Lymphat Cancer 2021;11:55-66. [PMID: 34354386 DOI: 10.2147/BLCTT.S267569] [Reference Citation Analysis]
|
